headerseite_nerv3
headerseite_nerv2
headerseite_bakterien
headerseite_nerv4
headerseite_dna
headerseite_binaer
headerseite_nerv1b
headerseite_chip
headerseite_befruchtung
headerseite_erythrozyten
headerseite_neurotrans
headerseite_wabe
headerseite_nerv1
Horizon2020Type of action: IMI2-RIA Research and Innovation action

Deadline: 14 June 2018




The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Currently, one of the most challenging questions in human immunology is to understand whether it is possible to accurately predict which patients will fail to respond to treatment, which patients will sustain a longer term treatment response, or which patients will suddenly flare up during periods of disease control. The topic addresses the challenge of translating insights from treatment non-response and disease exacerbation into new treatment paradigms at the individual patient level.

Do you need support with your Proposal, Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!

More information on the call